Here are the top 5 biosimilar articles for the week of September 22, 2025.

The Top 5 Biosimilar Articles for the Week of September 22

 Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq), the sixth pair of denosumab biosimilars to receive the green light from the agency. The approvals, granted to Biocon Biologics, will provide more affordable treatment options for people with osteoporosis and cancer-related bone conditions.

, a trastuzumab biosimilar that may help expand access to treatment for people with HER2-positive metastatic breast cancer, as a new real-world study from Fudan University Shanghai Cancer Center found it worked as well and was just as safe as the originator, even for patients who switched mid-treatment.

Number 3: Patients with inflammatory bowel disease (IBD) who transitioned from reference adalimumab (Humira) to the biosimilar Amgevita (adalimumab-atto) maintained stable disease control and generated substantial drug cost savings, according to a single-center 

 from Galway University Hospitals in Ireland.


Number 2: A new biosimilar, SYSA1902, shows 

 to ustekinumab for treating moderate-to-severe plaque psoriasis, expanding patient options.

Number 1: Sarfaraz K. Niazi, PhD, highlights the FDA’s move to 

 for biosimilars as a turning point that will lower development costs, drive big pharma out, and open the market to smaller companies, making biosimilars more affordable and accessible like generics.

Videos

The Top 5 Biosimilar Articles for the Week of September 1

 of 244 healthy stem cell donors found no new safety concerns with Sandoz’s filgrastim biosimilar, reinforcing its long-term safety for donor mobilization.

Number 4: A new biosimilar for aflibercept shows 

 in treating neovascular age-related macular degeneration (nAMD), enhancing patient access to treatment.

 in remission outcomes between etanercept biosimilars and the originator, Enbrel, for rheumatoid arthritis patients.


Number 2: Alvotech, an Iceland-based biosimilar-focused biotech company, marked a significant financial milestone in the 

, swinging from a substantial loss to a net profit, driven by the strong commercial performance of its key biosimilar products.

Number 1: The competitive landscape for bone health treatments in the US has intensified with the 

 of Bildyos (denosumab-nxxp) and Bilprevda (denosumab-nxxp), biosimilars to Amgen’s reference products Prolia and Xgeva, respectively.

Here are the top 5 biosimilar articles for the week of September 1, 2025.

Here are the top 5 biosimilar articles for the week of August 25, 2025.

, the first interchangeable insulin aspart biosimilar, enhancing access to affordable diabetes care for millions.

, audiences can discover the latest advancements in the biosimilar landscape, including the first patent lawsuit regarding a petuzumab biosimilar, a new ustekinumab biosimilar launch, and a new strategy for unbranded biosimilar access.

Number 3: New research confirms the romiplostim biosimilar GP40141 offers 

 for treating immune thrombocytopenia, enhancing treatment accessibility.

The Top 5 Biosimilar Articles for the Week of August 25

The top 5 biosimilar articles for the week of August 11, 2025

 struggles for market share in the UK, facing pricing challenges and prescriber inertia despite regulatory support and cost-saving potential.

 Explore the latest biosimilar developments, including legislative changes, new approvals, and challenges in understanding, 

 demonstrated equivalent efficacy in reducing HbA1c, along with comparable safety and immunogenicity profiles, to the reference drug dulaglutide in Chinese adults with type 2 diabetes.

 in HER2-positive advanced gastric cancer, achieving an 82% disease control rate in real-world settings.

, demonstrating comparable efficacy and safety in rheumatoid arthritis treatment, enhancing access and affordability.

To read all of these articles and more, visit 

Here are the top 5 biosimilar articles for the week of August 11, 2025.

The Top 5 Biosimilar Articles for the Week of August 11

Here are the top 5 biosimilar articles for the week of August 4, 2025.

 Biosimilars promise cost savings and improved patient access in Latin America, yet face significant 

 Patients with rheumatoid and psoriatic arthritis maintained stable disease activity and functional capacity, with even some improvement in ultrasound findings, after switching from 

 in biosimilars enhance access to affordable treatments for autoimmune disorders, bone diseases, and ophthalmic conditions.

, driving up costs and delaying affordable treatments. Discover legislative solutions to enhance competition and patient care.

 Real-world data confirm Mvasi's safety as a 

 to reference bevacizumab (Avastin) for treating retinal conditions.

The Top 5 Biosimilar Articles for the Week of August 4

Here are the top 5 biosimilar articles for the week of July 28, 2025.

 Global regulatory advancements in biosimilars 

 to affordable treatments for autoimmune disorders, bone diseases, and ophthalmic conditions.

 Government price negotiations under the 

 may hinder biosimilar development, impacting drug costs and patient access to affordable therapies.

 Real-world data confirm Mvasi's safety as a cost-effective alternative to reference 

 offers comparable effectiveness to Humira for ankylosing spondylitis, providing significant cost savings and improved patient retention rates.

The Top 5 Biosimilar Articles for the Week of July 28

Here are the top 5 biosimilar articles for the week of July 21, 2025.

 Sarfaraz K. Niazi, PhD, argues that the FDA can accelerate biosimilar entry by changing guidance under the 

Biologics Price Competition and Innovation Act (BPCIA)

 Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports 

 but foresees challenges adopting an intravenous daratumumab biosimilar, preferring the more convenient subcutaneous option.

the first interchangeable insulin aspart biosimilar

, enhancing access to affordable diabetes care for millions.

The Top 5 Biosimilar Articles for the Week of July 21

Here are the top 5 biosimilar articles for the week of July 14, 2025.

: Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges adopting an 

, preferring the more convenient subcutaneous option.

: Inpatient biosimilar use is expanding, especially in oncology and supportive care, presenting 

 for health systems while maintaining patient care quality.

safety and efficacy of biosimilar insulins

, addressing concerns and promoting their adoption for diabetes treatment.

 about biosimilars persist among consumers and healthcare professionals, hindering their adoption and potential benefits in health care.

 with new denosumab options, enhancing treatment for patients with osteoporosis and bone-related metastases.

The Top 5 Biosimilar Articles for the Week of July 14

Here are the top 5 biosimilar articles for the week of July 7, 2025.

: Long-term data from the SAME study confirm that 

 is safe and effective for patients with inflammatory bowel disease (IBD).

 persist among consumers and health care professionals, hindering their adoption and potential benefits in health care.

, including FDA approvals, patient switching trends, and real-world efficacy insights.

 demonstrated comparable efficacy and safety for paroxysmal nocturnal hemoglobinuria (PNH) to its reference drug, showing similar outcomes across diverse patient groups.

 switch back to the originator, according to research from Truveta. However, the presented data may not tell the full story.

The Top 5 Biosimilar Articles for the Week of July 7

Here are the top 5 biosimilar articles for the week of June 30, 2025.

 use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel disease (IBD) among children and young adults.

: About 13% of patients who switch from Humira to an adalimumab biosimilar switch back to the originator, according to research from Truveta. However, the presented data 

: A real-world study reveals that pediatric patients with IBD achieve 

: Regulators and manufacturers advance biosimilars for 

, enhancing access to treatment in Europe and Latin America.

 raises critical concerns about FDA standards, physician trust, and patient safety in biosimilars.